Literature DB >> 34847349

AUTHOR REPLY: The nuances of GRADE.

Trustin Domes1, Borna Tadayon Najafabadi2, Matthew Roberts3, Jeffrey Campbell4, Ryan Flannigan5, Phil Bach6, Premal Patel7, Gavin Langille8, Yonah Krakowsky9, Philippe D Violette10,2.   

Abstract

Entities:  

Year:  2021        PMID： 34847349      PMCID： PMC8631833          DOI： 10.5489/cuaj.7679

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN： 1911-6470            Impact factor:   1.862


× No keyword cloud information.
  10 in total

Review 1.  The International Index of Erectile Function (IIEF): a state-of-the-science review.

Authors:  R C Rosen; J C Cappelleri; N Gendrano
Journal:  Int J Impot Res       Date:  2002-08       Impact factor: 2.896

2.  GRADE: an emerging consensus on rating quality of evidence and strength of recommendations.

Authors:  Gordon H Guyatt; Andrew D Oxman; Gunn E Vist; Regina Kunz; Yngve Falck-Ytter; Pablo Alonso-Coello; Holger J Schünemann
Journal:  BMJ       Date:  2008-04-26

3.  GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: Introduction.

Authors:  Pablo Alonso-Coello; Holger J Schünemann; Jenny Moberg; Romina Brignardello-Petersen; Elie A Akl; Marina Davoli; Shaun Treweek; Reem A Mustafa; Gabriel Rada; Sarah Rosenbaum; Angela Morelli; Gordon H Guyatt; Andrew D Oxman
Journal:  BMJ       Date:  2016-06-28

4.  Treatment strategy for "non-responders" to tadalafil and vardenafil: a real-life study.

Authors:  Konstantinos Hatzimouratidis; Kyriakos Moysidis; Athanasios Bekos; Zoi Tsimtsiou; Evangelos Ioannidis; Dimitrios Hatzichristou
Journal:  Eur Urol       Date:  2006-03-10       Impact factor: 20.096

5.  Efficacy and safety of daily tadalafil in men with erectile dysfunction previously unresponsive to on-demand tadalafil.

Authors:  Chris McMahon
Journal:  J Sex Med       Date:  2004-11       Impact factor: 3.802

6.  Comparison of efficacy, safety, and tolerability of on-demand tadalafil and daily dosed tadalafil for the treatment of erectile dysfunction.

Authors:  Chris McMahon
Journal:  J Sex Med       Date:  2005-05       Impact factor: 3.802

7.  Couples' reasons for adherence to, or discontinuation of, PDE type 5 inhibitors for men with erectile dysfunction at 12 to 24-month follow-up after a 6-month free trial.

Authors:  Helen M Conaglen; John V Conaglen
Journal:  J Sex Med       Date:  2012-01-12       Impact factor: 3.802

8.  Canadian Urological Association guideline: Erectile dysfunction.

Authors:  Trustin Domes; Borna Tadayon Najafabadi; Matthew Roberts; Jeffrey Campbell; Ryan Flannigan; Phil Bach; Premal Patel; Gavin Langille; Yonah Krakowsky; Philippe D Violette
Journal:  Can Urol Assoc J       Date:  2021-10       Impact factor: 1.862

9.  Investigating women's preference for sildenafil or tadalafil use by their partners with erectile dysfunction: the partners' preference study.

Authors:  Helen M Conaglen; John V Conaglen
Journal:  J Sex Med       Date:  2008-02-25       Impact factor: 3.802

Review 10.  Meta-Analysis of the Long-Term Efficacy and Tolerance of Tadalafil Daily Compared With Tadalafil On-Demand in Treating Men With Erectile Dysfunction.

Authors:  Zhongbao Zhou; Hongyan Chen; Jitao Wu; Jipeng Wang; Xuebao Zhang; Jiajia Ma; Yuanshan Cui
Journal:  Sex Med       Date:  2019-07-12       Impact factor: 2.491
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.